Multiple Sclerosis Drugs Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

1 RESEARCH SCOPE

1.1 Research Product Definition

1.2 Research Segmentation

1.2.1 Product Type

1.2.2 Main product Type of Major Players

1.3 Demand Overview

1.4 Research Methodology

2 GLOBAL MULTIPLE SCLEROSIS DRUGS INDUSTRY

2.1 Summary about Multiple Sclerosis Drugs Industry

2.2 Multiple Sclerosis Drugs Market Trends

2.2.1 Multiple Sclerosis Drugs Production & Consumption Trends

2.2.2 Multiple Sclerosis Drugs Demand Structure Trends

2.3 Multiple Sclerosis Drugs Cost & Price

3 MARKET DYNAMICS

3.1 Manufacturing & Purchasing Behavior in 2020

3.2 Market Development under the Impact of COVID-19

3.2.1 Drivers

3.2.2 Restraints

3.2.3 Opportunity

3.2.4 Risk

4 GLOBAL MARKET SEGMENTATION

4.1 Region Segmentation (2017 to 2021f)

4.1.1 North America (U.S., Canada and Mexico)

4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)

4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)

4.1.4 South America (Brazil,, Argentina, Rest of Latin America)

4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)

4.2 Product Type Segmentation (2017 to 2021f)

4.2.1 Oral 

4.2.2 Injectable 

4.2.3 Intravenous

4.3 Consumption Segmentation (2017 to 2021f)

4.3.1 Hospital Pharmacy 

4.3.2 Retail Pharmacy 

4.3.3 Online Pharmacy

5 NORTH AMERICA MARKET SEGMENT

5.1 Region Segmentation (2017 to 2021f)

5.1.1 U.S.

5.1.2 Canada

5.1.3 Mexico

5.2 Product Type Segmentation (2017 to 2021f)

5.2.1 Oral 

5.2.2 Injectable 

5.2.3 Intravenous

5.3 Consumption Segmentation (2017 to 2021f)

5.3.1 Hospital Pharmacy 

5.3.2 Retail Pharmacy 

5.3.3 Online Pharmacy

5.4 Impact of COVID-19 in North America

6 EUROPE MARKET SEGMENTATION

6.1 Region Segmentation (2017 to 2021f)

6.1.1 Germany

6.1.2 UK

6.1.3 France

6.1.4 Italy

6.1.5 Rest of Europe

6.2 Product Type Segmentation (2017 to 2021f)

6.2.1 Oral 

6.2.2 Injectable 

6.2.3 Intravenous

6.3 Consumption Segmentation (2017 to 2021f)

6.3.1 Hospital Pharmacy 

6.3.2 Retail Pharmacy 

6.3.3 Online Pharmacy

6.4 Impact of COVID-19 in Europe

7 ASIA-PACIFIC MARKET SEGMENTATION

7.1 Region Segmentation (2017 to 2021f)

7.1.1 China

7.1.2 India

7.1.3 Japan

7.1.4 South Korea

7.1.5 Southeast Asia

7.1.6 Australia

7.1.7 Rest of Asia Pacific

7.2 Product Type Segmentation (2017 to 2021f)

7.2.1 Oral 

7.2.2 Injectable 

7.2.3 Intravenous

7.3 Consumption Segmentation (2017 to 2021f)

7.3.1 Hospital Pharmacy 

7.3.2 Retail Pharmacy 

7.3.3 Online Pharmacy

7.4 Impact of COVID-19 in Europe

8 SOUTH AMERICA MARKET SEGMENTATION

8.1 Region Segmentation (2017 to 2021f)

8.1.1 Brazil

8.1.2 Argentina

8.1.3 Rest of Latin America

8.2 Product Type Segmentation (2017 to 2021f)

8.2.1 Oral 

8.2.2 Injectable 

8.2.3 Intravenous

8.3 Consumption Segmentation (2017 to 2021f)

8.3.1 Hospital Pharmacy 

8.3.2 Retail Pharmacy 

8.3.3 Online Pharmacy

8.4 Impact of COVID-19 in Europe

9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION

9.1 Region Segmentation (2017 to 2021f)

9.1.1 GCC

9.1.2 North Africa

9.1.3 South Africa

9.1.4 Rest of Middle East and Africa

9.2 Product Type Segmentation (2017 to 2021f)

9.2.1 Oral 

9.2.2 Injectable 

9.2.3 Intravenous

9.3 Consumption Segmentation (2017 to 2021f)

9.3.1 Hospital Pharmacy 

9.3.2 Retail Pharmacy 

9.3.3 Online Pharmacy

9.4 Impact of COVID-19 in Europe

10 COMPETITION OF MAJOR PLAYERS

10.1 Brief Introduction of Major Players

10.1.1 Biogen 

10.1.2 Teva Pharmaceutical 

10.1.3 Merck KGaA 

10.1.4 Novartis 

10.1.5 Bayer 

10.1.6 Sanofi 

10.1.7 Acorda Therapeutics 

10.1.8 Questcor Pharmaceuticals

10.2 Multiple Sclerosis Drugs Sales Date of Major Players (2017-2020e)

10.2.1 Biogen 

10.2.2 Teva Pharmaceutical 

10.2.3 Merck KGaA 

10.2.4 Novartis 

10.2.5 Bayer 

10.2.6 Sanofi 

10.2.7 Acorda Therapeutics 

10.2.8 Questcor Pharmaceuticals

10.3 Market Distribution of Major Players

10.4 Global Competition Segmentation

11 MARKET FORECAST

11.1 Forecast by Region

11.2 Forecast by Demand

11.3 Environment Forecast

11.3.1 Impact of COVID-19

11.3.2 Geopolitics Overview

11.3.3 Economic Overview of Major Countries

12 REPORT SUMMARY STATEMENT

Table Multiple Sclerosis Drugs Product Type Overview

Table Multiple Sclerosis Drugs Product Type Market Share List

Table Multiple Sclerosis Drugs Product Type of Major Players

Table Brief Introduction of Biogen 

Table Brief Introduction of Teva Pharmaceutical 

Table Brief Introduction of Merck KGaA 

Table Brief Introduction of Novartis 

Table Brief Introduction of Bayer 

Table Brief Introduction of Sanofi 

Table Brief Introduction of Acorda Therapeutics 

Table Brief Introduction of Questcor Pharmaceuticals

Table Products & Services of Biogen 

Table Products & Services of Teva Pharmaceutical 

Table Products & Services of Merck KGaA 

Table Products & Services of Novartis 

Table Products & Services of Bayer 

Table Products & Services of Sanofi 

Table Products & Services of Acorda Therapeutics 

Table Products & Services of Questcor Pharmaceuticals

Table Market Distribution of Major Players

Table Global Major Players Sales Revenue (Million USD) 2017-2020e

Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e

Table Global Multiple Sclerosis Drugs Market Forecast (Million USD) by Region 2021f-2026f

Table Global Multiple Sclerosis Drugs Market Forecast (Million USD) Share by Region 2021f-2026f

Table Global Multiple Sclerosis Drugs Market Forecast (Million USD) by Demand 2021f-2026f

Table Global Multiple Sclerosis Drugs Market Forecast (Million USD) Share by Demand 2021f-2026f